EpendymomaSymptoms, Doctors, Treatments, Advances & More
Learn About Ependymoma
View Main Condition: Brain Tumor
Johns Hopkins Outpatient Center
Chetan Bettegowda is a Neurosurgery provider practicing medicine in Baltimore, Maryland. Dr. Bettegowda is rated as an Elite provider by MediFind in the treatment of Ependymoma. He is also highly rated in 39 other conditions, according to our data. His clinical expertise encompasses Trigeminal Neuralgia, Astrocytoma, Glioblastoma, Rhizotomy, and Microvascular Decompression. Dr. Bettegowda is board certified in American Board Of Neurological Surgery. Dr. Bettegowda is currently accepting new patients.
UMass Memorial Health - Marlborough Campus
David Cachia is a Neurologist and an Oncologist practicing medicine in Marlborough, Massachusetts. Dr. Cachia is rated as a Distinguished provider by MediFind in the treatment of Ependymoma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Ependymoma. Dr. Cachia is board certified in Neurology and Neuro-Oncology. Dr. Cachia is currently accepting new patients.
Duke Cancer Center Brain Tumor Clinic
Allan Friedman is a Neurosurgery provider practicing medicine in Durham, North Carolina. Dr. Friedman is rated as a Distinguished provider by MediFind in the treatment of Ependymoma. He is also highly rated in 43 other conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, Awake Craniotomy, and Laminectomy. Dr. Friedman is board certified in American Board Of Neurological Surgery, Neurological Surgery. Dr. Friedman is currently accepting new patients.
Summary: This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
Summary: The purpose of this research study is to test the safety and effectiveness of a cell therapy at different doses for children and young adults with recurrent or progressive brain tumors. Recurrent/recurred means a tumor that has gone away and then came back. This cell therapy is called B7- H3.CD28Z.CART, referred to as B7-H3 CAR T cells. B7-H3 is a protein that is over-expressed on many tumor cells...